資源描述：
《纈沙坦聯(lián)合貝那普利治療糖尿病腎病療效觀察》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、緘沙坦聯(lián)合貝那普利治療糖尿病腎病療效觀察［摘要］目的觀察頷沙坦聯(lián)合貝那普利治療糖尿病腎病的療效。方法將20"年1月~2012年1月于我院住院的2型糖尿病腎病患者80例隨機分為貝那普利組（27例X頌沙坦組（26例）.頌沙坦聯(lián)合貝那普利組（聯(lián)合組，27例）,三組患者均連續(xù)給予控制血糖和血壓治療2周在此基礎(chǔ)上，三組分別采用貝那普利、頌沙坦、頌沙坦聯(lián)合貝那普利治療,均連續(xù)治療12周。對所有患者的血壓、空腹血糖（FPG,血清電解質(zhì)（K+X血尿素氮（BUN）及血肌酹（SCr,肌酹清除率（Ccr）及24h尿蛋白進行觀察，同時記錄不良反應(yīng)。結(jié)果三組治
2、療前后血壓、24h尿蛋白治療后與治療前比較，差異均有統(tǒng)計學意義（P<0.05）,治療后聯(lián)合組與與貝那普利組、纟頡沙坦組比較，差異有統(tǒng)計學意義（P<0.05三組治療前后FPG、K+、BUN、SCr、Ccr及不良反應(yīng)的比較差異均無統(tǒng)計學意義（P>0.05）b結(jié)論頷沙坦聯(lián)合貝那普利治療糖尿病腎病患者的血壓、尿蛋白方面療效較單一用藥好，臨床可安全應(yīng)用。［關(guān)鍵詞］纟頡沙坦；貝那普利；糖尿病腎??；臨床療效［中圖分類號］R587.2只692.3［文獻標識碼］A［文章編號］1673-7210(2012)07(b)-0065-02Clinicalob
3、servationofValsartancombinedwithBenazeprilinthetreatmentofdiabeticnephropathyLIXionglCHENTing2CAIDelZHONGZhi1DepartmentofPharmacy,theAffiliatedHospitalofGuangdongMedicalCollege,GuangdongProvince,Zhanjiang524001,China;2.DepartmentofNephrology,theAffiliatedHospitalofGuang
4、dongMedicalCollege,GuangdongProvinee,Zhanjiang524001,China[Abstract]ObjectiveToobservetheeffectofValsartancombinedwithBenazeprilinthetreatmentofdiabeticnephropathy.Methods80patientswithdiabeticnephropathyfromJanuary2011toJanuary2012inourhospitalweredividedintothreegroup
5、s:Valsartangroup(27cases),Benazeprilgroup(26cases),ValsartancombinedwithBenazeprilgroup(combinedgroup,27cases).Threegroupsofpatientswerecontinuouslygiventocontrolbloodsugarandbloodpressuretreatmentfor2weeks,onthebasis,Valsartan,Benazeprilandcombineddrugsweregiventhethre
6、egroups,andthetotaltimeofthetreatmentwas12weeks.Andbloodpressure,fastingplasmaglucose(FPG),serumelectrolytes(K+),bloodureanitrogen(BUN)andserumcreatinine(SCr),creatinineclearaneerate(Ccr)and24hurinaryproteinforallpatientswereobserved,andtheadversereactionswererecorded,R
7、esultsBeforeandaftertreatmentinthreegroups,bloodpressure,24hurinaryproteinaftertreatmentwerecompared,thereweresignificantdifferences(P<0.05),thecombinedgroupcomparedwiththeBenazeprilgroupandValsartangroup,thereweresignificantdifferences(P<0.05).FPG,K+,BUN,andSCrandCcran
8、dadversereactionsinthethreegroupsbeforeandaftertreatmentshowednosignificantdifferences(P>0.05).ConclusionValsa
